Dyadic Updates its Progress in Development of Enzymes for Conversion of Biomass to Cellulosic Ethanol at Third Annual BIO Confe
13 Juillet 2006 - 1:45PM
Business Wire
Dyadic International, Inc. (AMEX:DIL), a biotechnology company,
will report today at the Third Annual World Congress on Industrial
Biotechnology and Bioprocessing in Toronto, Canada, that it has
identified and tested highly effective enzyme mixtures for the
efficient conversion of renewable cellulosic biomass to ethanol.
"We are making meaningful strides toward the production of low-cost
ethanol from biomass," said Dr. Glenn Nedwin, Chief Science Officer
of Dyadic. Dyadic scientist Marco Baez, Ph.D. will present results
of an internal study on Dyadic's proprietary cellulase and
hemicellulase mixes with strong saccharifying activity on a number
of different lignocellulosic feedstocks, including Douglas fir and
cotton. In addition, Dr. Baez will present data showing the results
of an internal study of two new highly active cellobiohydrolases
isolated from Dyadic's patented Chrysosporium lucknowense fungal
strain (known as C1), as well as a mixture of pure monocomponent
enzymes, all of which demonstrated an extremely high ability to
convert different cellulosic substrates to glucose, the critical
raw material for the production of ethanol. "The key hurdles that
must be overcome for the large-scale commercial production of
low-cost ethanol from renewable biomass are to reduce the cost and
increase the efficiency of the enzymes used to extract glucose and
other sugars from the cellulolytic feedstocks," Dr. Nedwin
explained. "Dyadic has been a leader in the saccharification of
cellulosic substrates for more than a decade. The results to be
presented today show that we are making rapid progress in the
development of potent enzyme mixtures that work well in the
cellulosic ethanol application. Dyadic has filed a patent
application with the U.S. Patent Office for these new enzymes and
mixtures containing these enzymes. This is in addition to the
Company's many other patents already issued or pending which
protect our technology in this area." Separately, Dyadic noted that
in a recent publication (BC Saha and M.A. Cotta, Biotech. Prog.
22:449-453, 2006), researchers at the U.S. Department of
Agriculture measured the efficiency of various commercially
available enzyme preparations (including Dyadic's Viscostar 150L)
on wheat straw pretreated with alkaline peroxide for the extraction
of glucose and other sugars. The authors of this study stated that
"unlike corn fiber hemicellulose, which is very resistant to
hydrolysis using commercial enzymes, wheat straw hemicellulose can
be easily hydrolyzed enzymatically by using a single xylanase
preparation (Viscostar) after alkaline peroxide treatment." The
Third Annual World Congress on Industrial Biotechnology and
Bioprocessing, taking place from July 11 to July 14, 2006 in
Toronto, Canada, hosted by the Biotechnology Industry Organization
(BIO), American Chemical Society, the National Agriculture
Biotechnology Council, the Agri-Food Innovation Forum, the Chemical
Institute of Canada, BIOTECanada and EuropaBIO, is the premiere
gathering of thought leaders, investors, researchers and business
executives in industrial biotechnology, bioenergy and
bioprocessing. About Dyadic Dyadic International, Inc. is engaged
in the development, manufacture and sale of biological products
using a number of proprietary fungal strains to produce enzymes and
other biomaterials, principally focused on a system for protein
production based on the patented Chrysosporium lucknowense fungus,
known as C1. Dyadic is applying its technologies to produce enzymes
for use in converting various agricultural products (e.g. corn) and
waste products (e.g. switch grass, wheat straw, sugar cane bagasse,
etc.) into fermentable sugars, which can then be used in the
production of traditional and cellulosic ethanol as well as other
products currently derived from petroleum. Dyadic's C1 technology
also is being developed to facilitate the discovery, development
and large-scale production of human antibodies and other high-value
therapeutic proteins. Dyadic currently sells more than 45 liquid
and dry enzyme products to more than 200 industrial customers in
approximately 50 countries for the textile, pulp & paper and
animal feed industries. Cautionary Statement for Forward-Looking
Statements Certain statements contained in this press release are
"forward-looking statements." These forward-looking statements
involve risks and uncertainties that could cause our actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied by such forward-looking statements. For a discussion of
these risks and uncertainties, please see our filings from time to
time with the Securities and Exchange Commission, which are
available free of charge on the SEC's web site at
http://www.sec.gov, including our Annual Report on Form 10-KSB for
the year ended December 31, 2005, and our Quarterly Report on Form
10-QSB for the quarter ended March 31, 2006. Except as required by
law, we expressly disclaim any intent or obligation to update any
forward-looking statements.
Dyadic (AMEX:DIL)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Dyadic (AMEX:DIL)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024